Lexeo Therapeutics, Inc. Common Stock
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- R. Nolan Townsend
- Full Time Employees
- 75
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 345 Park Avenue South New York City United States of America 10010
- IPO Date
- Nov 3, 2023
- CIK
- 0001907108
- Website
- lexeotx.com
- Similar Companies
- Business
- Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing innovative gene therapy treatments for hereditary and acquired cardiovascular diseases and APOE4-associated Alzheimer's disease. The company’s primary products include gene therapy candidates such as LX2006 for Friedreich’s ataxia (FA) cardiomyopathy; LX2020 targeting plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy; LX2021 for DSP cardiomyopathy; and LX2022 for hypertrophic cardiomyopathy caused by TNNI3 gene mutations. Lexeo develops these therapies using adeno-associated virus (AAV) based platforms and advanced genetic medicine technologies, aiming to address diseases with significant unmet medical needs. Headquartered in New York City and founded in the early 2020s, the company builds on pioneering research from institutions like Weill Cornell Medicine and the University of California San Diego and operates in the United States with a focus on global clinical development. Recent major developments include securing the U.S. FDA Breakthrough Therapy designation for LX2006, which accelerates its regulatory pathway for treating Friedreich’s ataxia cardiomyopathy; inclusion in the FDA's Chemistry, Manufacturing, and Controls Readiness Pilot program to streamline manufacturing processes; and significant progress in Phase I/II clinical trials demonstrating promising interim efficacy data. In mid-2025, Lexeo announced a strategic partnership with Perceptive Xontogeny Venture Funds and venBio Partners to develop non-viral RNA-based therapeutics for genetic cardiac diseases, supported by up to $40 million in private equity financing. This collaboration led to the creation of a new entity leveraging Lexeo’s expertise and preclinical intellectual property, with future milestone payments and royalties structured for Lexeo. Additionally, Lexeo closed an $80 million equity financing round to support its clinical pipeline, including ongoing advancements in LX2020 and other programs, and appointed new key leadership to strengthen its financial and operational capabilities. Lexeo’s innovative product pipeline targets cardiovascular and neurodegenerative disorders primarily in the genetic medicine and biotechnology industry segments. The company’s products are oriented toward patients suffering from rare genetic cardiac diseases and neurodegenerative conditions, with an emphasis on gene therapy and RNA-based therapeutic modalities. Lexeo Therapeutics continues to expand its pipeline and clinical development programs and engages with key stakeholders through scientific forums and virtual events to share progress and insights on managing genetic cardiac diseases. The company’s focus on precision genetic medicine and next-generation delivery platforms positions it at the forefront of transformative treatments for genetic diseases within the United States and globally.
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $19.00 Consensus Target Price from Analysts
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference
Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells $64,903.74 in Stock
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of “Moderate Buy” by Brokerages
Lexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics
Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 9% – Here’s Why
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Lexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
Wall Street Analysts Predict a 124.3% Upside in Lexeo Therapeutics, Inc. (LXEO): Here's What You Should Know
Lexeo Therapeutics: Behind The Rebound